Muhammad Naseem Khan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Muhammad Naseem Khan has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Taha
Department of Clinical Pharmacy, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
7 shared publications Hayat Ullah
Department of Chemistry, Hazara University, Mansehra 21300, Pakistan
4 shared publicationsMuhammad Ali
University of Nizwa
4 shared publicationsFazal Rahim
Department of Chemistry, Hazara University, Mansehra 21300, Pakistan
3 shared publications- Fazal Rahim
Department of Chemistry , Hazara University , Mansehra , 21120 , Pakistan
3 shared publications Khalid Mohammed Khan
H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Pakistan
3 shared publications
Latest Publications
- Open Access
- 9 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0321500
Unraveling potential EGFR kinase inhibitors: Computational screening, molecular dynamics insights, and MMPBSA analysis for targeted cancer therapy development
EGFR is critical for tumor angiogenesis and cancer progression, but existing treatments like erlotinib face limitations such as acquired resistance and side effects. To address these issues, this study employs structure-based drug design techniques including virtual screening, molecular docking, and molecular dynamics simulations to identify new small molecule inhibitors targeting the EGFR kinase domain. From an initial selection of 633,000 compounds from diverse databases, top candidates were identified based on their binding affinity and stability. The virtual screening and docking analyses revealed compounds with higher binding scores than erlotinib. Molecular dynamics simulations and Anisotropic Network Model (ANM) analysis uniquely report that EGFR undergoes significant conformational shifts: inward flap movements in the bound state stabilize a closed conformation, while outward movements in the free state result in a more open conformation. Among the identified inhibitors, compounds such as JFD00243, NPA015124, and others exhibited strong binding affinities and stable interactions with both active and inactive forms of EGFR. Notably, JFD00243 was effective in targeting EGFR in both active and inactive conformations. These findings suggest that the identified inhibitors could potentially overcome current treatment limitations and improve targeted cancer therapies by effectively inhibiting EGFR-mediated tumor angiogenesis.
- 9 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0321500
Open AccessUnraveling potential EGFR kinase inhibitors: Computational screening, molecular dynamics insights, and MMPBSA analysis for targeted cancer therapy development
EGFR is critical for tumor angiogenesis and cancer progression, but existing treatments like erlotinib face limitations such as acquired resistance and side effects. To address these issues, this study employs structure-based drug design techniques including virtual screening, molecular docking, and molecular dynamics simulations to identify new small molecule inhibitors targeting the EGFR kinase domain. From an initial selection of 633,000 compounds from diverse databases, top candidates were identified based on their binding affinity and stability. The virtual screening and docking analyses revealed compounds with higher binding scores than erlotinib. Molecular dynamics simulations and Anisotropic Network Model (ANM) analysis uniquely report that EGFR undergoes significant conformational shifts: inward flap movements in the bound state stabilize a closed conformation, while outward movements in the free state result in a more open conformation. Among the identified inhibitors, compounds such as JFD00243, NPA015124, and others exhibited strong binding affinities and stable interactions with both active and inactive forms of EGFR. Notably, JFD00243 was effective in targeting EGFR in both active and inactive conformations. These findings suggest that the identified inhibitors could potentially overcome current treatment limitations and improve targeted cancer therapies by effectively inhibiting EGFR-mediated tumor angiogenesis.
- Open Access
Synthesis of Chromen-4-One-Oxadiazole Substituted Analogs as Potent β-Glucuronidase Inhibitors
Chromen-4-one substituted oxadiazole analogs 1–19 have been synthesized, characterized and evaluated for β-glucuronidase inhibition. All analogs exhibited a variable degree of β-glucuronidase inhibitory activity with IC50 values ranging in between 0.8 ± 0.1–42.3 ± 0.8 μM when compared with the standard d-saccharic acid 1,4 lactone (IC50 = 48.1 ± 1.2 μM). Structure activity relationship has been established for all compounds. Molecular docking studies were performed to predict the binding interaction of the compounds with the active site of enzyme.
Open AccessSynthesis of Chromen-4-One-Oxadiazole Substituted Analogs as Potent β-Glucuronidase Inhibitors
Chromen-4-one substituted oxadiazole analogs 1–19 have been synthesized, characterized and evaluated for β-glucuronidase inhibition. All analogs exhibited a variable degree of β-glucuronidase inhibitory activity with IC50 values ranging in between 0.8 ± 0.1–42.3 ± 0.8 μM when compared with the standard d-saccharic acid 1,4 lactone (IC50 = 48.1 ± 1.2 μM). Structure activity relationship has been established for all compounds. Molecular docking studies were performed to predict the binding interaction of the compounds with the active site of enzyme.
- 1 November 2018
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 15 (11) , 2441-2454
Synthesis, β-Glucuronidase Inhibition, and Molecular Docking Studies of 1,2,4-Triazole Hydrazones
- 1 November 2018
- Published by Springer Nature in Journal of the Iranian Chemical Society
- Vol. 15 (11) , 2441-2454
Synthesis, β-Glucuronidase Inhibition, and Molecular Docking Studies of 1,2,4-Triazole Hydrazones
- 1 October 2018
- Published by Elsevier in Bioorganic Chemistry
- Vol. 80, 36-42
Synthesis, α-amylase inhibitory potential and molecular docking study of indole derivatives
- 1 October 2018
- Published by Elsevier in Bioorganic Chemistry
- Vol. 80, 36-42
Synthesis, α-amylase inhibitory potential and molecular docking study of indole derivatives
- 1 January 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (1) , 152-160
Bisindolylmethane thiosemicarbazides as potential inhibitors of urease: Synthesis and molecular modeling studies
- 1 January 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (1) , 152-160
Bisindolylmethane thiosemicarbazides as potential inhibitors of urease: Synthesis and molecular modeling studies
- 1 January 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 143, 1757-1767
Synthesis of bis-indolylmethanes as new potential inhibitors of β-glucuronidase and their molecular docking studies
- 1 January 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 143, 1757-1767
Synthesis of bis-indolylmethanes as new potential inhibitors of β-glucuronidase and their molecular docking studies
- 1 October 2016
- Published by Elsevier in Bioorganic Chemistry
- Vol. 68, 30-40
Synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory potential of hydrazide based Schiff bases
- 1 October 2016
- Published by Elsevier in Bioorganic Chemistry
- Vol. 68, 30-40
Synthesis and in vitro acetylcholinesterase and butyrylcholinesterase inhibitory potential of hydrazide based Schiff bases
- 1 October 2015
- Published by Elsevier in Bioorganic Chemistry
- Vol. 62, 15-21
Synthesis, in vitro evaluation and molecular docking studies of thiazole derivatives as new inhibitors of α-glucosidase
- 1 October 2015
- Published by Elsevier in Bioorganic Chemistry
- Vol. 62, 15-21
Synthesis, in vitro evaluation and molecular docking studies of thiazole derivatives as new inhibitors of α-glucosidase